6 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 6 of 6 clinical reviews.
A deep clinical review of the methodology flaws, enrollment biases, generalizability gaps, statistical caveats, and conflict-of-interest concerns that qualify the ORIGIN trial's neutral cardiovascular findings for insulin glargine in dysglycemia.
A detailed breakdown of the ORIGIN trial's randomization, blinding, endpoint adjudication, comparator rationale, and statistical framework, and why each design choice matters for interpreting cardiovascular safety of insulin glargine in early dysglycemia.
Deep dive into the ORIGIN trial follow-up: long-term outcomes after insulin glargine vs standard care in early dysglycemia, durability of glycemic effects, and cardiovascular safety signals over extended observation.
Health-economic analyses from the ORIGIN trial examining cost per QALY of insulin glargine vs standard care in early dysglycemia, payer implications, and value calculations for patients.
A plain-English deep dive into the ORIGIN trial, which tested whether early insulin glargine could prevent cardiovascular events in people with dysglycemia. Full methodology, results, and clinical implications.
How the ORIGIN trial's neutral cardiovascular findings for insulin glargine reshaped guidelines, prescribing behavior, and risk conversations for early dysglycemia management.